A late onset Parkinson disease that has material basis in heterozygous triplication of the alpha-synuclein gene (SNCA) on chromosome 4q22.
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
The limited documentation surrounding autosomal dominant Parkinson disease 4 reflects the rarity of the condition, which affects fewer individuals and has not been extensively studied. Additionally, the genetic basis was only recently identified, and ongoing clinical characterization is necessary to better understand its phenotypic variability. This can understandably lead to frustration for patients and families seeking more comprehensive information.
To navigate your care effectively, consider consulting a neurologist with expertise in hereditary movement disorders, particularly those familiar with genetic forms of Parkinson's disease. Genetic counseling may also be beneficial to understand the implications of the SNCA gene triplication for you and your family. While there are no specific patient organizations identified for this condition, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information and support. Participating in clinical trials could also be an option to explore potential treatments and contribute to research.
Currently, there are 92 active clinical trials related to autosomal dominant Parkinson disease 4, which indicates ongoing research efforts to better understand and potentially treat this condition. While there are no orphan drug designations for this specific condition, the active trials may explore various therapeutic approaches. For more information on these trials, you can visit ClinicalTrials.gov and search for 'autosomal dominant Parkinson disease 4'.
Actionable guidance for navigating care for autosomal dominant Parkinson disease 4
To navigate your care effectively, consider consulting a neurologist with expertise in hereditary movement disorders, particularly those familiar with genetic forms of Parkinson's disease. Genetic counseling may also be beneficial to understand the implications of the SNCA gene triplication for you and your family. While there are no specific patient organizations identified for this condition, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information and support. Participating in clinical trials could also be an option to explore potential treatments and contribute to research.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Inheritance patterns describe how genetic conditions are passed from parents to children.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.